Brief: Amylyx Pharmaceuticals Receives Orphan Drug Designation From The European Commission For Amx0035
02/08/2024 23:16
Aug 2 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O :
* AMYLYX PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION
FROM THE
EUROPEAN COMMISSION FOR AMX0035 FOR THE TREATMENT OF WOLFRAM
SYNDROME
* TOPLINE DATA FOR PHASE 2 HELIOS TRIAL ANTICIPATED FALL
2024
Source text for Eikon: ID:nBw9QBT3za
Further company coverage: AMLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock